UroGen Pharma Ltd.
URGN
$18.44
-$0.35-1.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 109.79M | 96.52M | 94.24M | 91.87M | 90.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 109.79M | 96.52M | 94.24M | 91.87M | 90.40M |
| Cost of Revenue | 12.45M | 11.63M | 10.80M | 9.48M | 8.88M |
| Gross Profit | 97.34M | 84.89M | 83.43M | 82.39M | 81.52M |
| SG&A Expenses | 155.10M | 151.71M | 143.07M | 129.92M | 122.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 234.65M | 231.02M | 218.90M | 200.93M | 188.28M |
| Operating Income | -124.86M | -134.51M | -124.67M | -109.06M | -97.88M |
| Income Before Tax | -153.42M | -161.64M | -150.82M | -135.26M | -124.04M |
| Income Tax Expenses | 78.00K | 3.00M | 4.15M | 3.17M | 2.83M |
| Earnings from Continuing Operations | -153.49 | -164.64 | -154.97 | -138.43 | -126.87 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -153.49M | -164.64M | -154.97M | -138.43M | -126.87M |
| EBIT | -124.86M | -134.51M | -124.67M | -109.06M | -97.88M |
| EBITDA | -123.65M | -133.31M | -124.38M | -108.78M | -97.55M |
| EPS Basic | -3.20 | -3.46 | -3.27 | -3.05 | -3.00 |
| Normalized Basic EPS | -2.00 | -2.14 | -2.01 | -1.88 | -1.85 |
| EPS Diluted | -3.20 | -3.46 | -3.27 | -3.05 | -3.00 |
| Normalized Diluted EPS | -2.00 | -2.14 | -2.01 | -1.88 | -1.85 |
| Average Basic Shares Outstanding | 192.45M | 190.25M | 188.97M | 181.73M | 171.37M |
| Average Diluted Shares Outstanding | 192.45M | 190.25M | 188.97M | 181.73M | 171.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |